Scientists discover gene tied to profound vision loss

January 15, 2015

An exhaustive hereditary analysis of a large Louisiana family with vision issues has uncovered a new gene tied to an incurable eye disorder called retinitis pigmentosa, according to an examination led by scientists at The University of Texas Health Science Center at Houston (UTHealth). It is a family of eye diseases that affects more than 200,000 people in the United States and millions worldwide.

The retina converts images into electrical signals that can be processed by the brain. It acts much like the film in a camera. Retinitis pigmentosa damages this film (the retina) and its early symptoms include decreased night vision and peripheral vision. Once it starts, the loss of vision is relentlessly progressive, often ending in blindness.

In the journal Investigative Ophthalmology & Visual Science, UTHealth's Stephen P. Daiger, Ph.D., and his colleagues report their discovery of a new gene tied to retinitis pigmentosa, which brings the total of genes associated with this sight-threatening disease to more than 60. The gene is called hexokinase 1 (HK1).

This information is important because it helps affected families cope with the disorder, helps explain the biologic basis of these diseases and suggests targets for drug treatments and gene therapy, said Daiger, the report's senior author and holder of the Thomas Stull Matney Ph.D. Endowed Professorship in Environmental and Genetic Sciences at UTHealth School of Public Health.

"The challenge now is to block the activity of these mutations and clinical trials are underway to do just that," he said.

"Dr. Daiger is trying to make a breakthrough in potentially blinding diseases with no known treatments," said Richard S. Ruiz, M.D., professor of ophthalmology and holder of the John S. Dunn Distinguished University Chair in Ophthalmology at UTHealth. "Right now, we address the symptoms of the disease and help patients make the most of their existing vision."

For approximately three decades, Daiger, a member of the Human Genetics Center at the UTHealth School of Public Health, has been following the progress of hundreds of families across the country with retinitis pigmentosa. "We've found the cause of disease in 80 percent of the families we have studied," Daiger said. "Our goal is to find the cause in the remaining 20 percent."

Equipped with the genetic profiles of family members, Daiger's team has identified differences in the genetic makeup of those with the disease. The researchers also use family histories and DNA tests to glean information about the condition's hereditary nature.

There are different types of retinitis pigmentosa and Daiger's laboratory is focused on the autosomal dominant type. This means that only one parent needs the mutation in order to pass the disease to a child. This type accounts for about a third of all cases and many of its disease-causing genes have been discovered, several by Daiger's research group.

"The story of the HK1 mutation is itself interesting. What we found is a mutation present in families from Louisiana, Canada and Sicily. Our evidence suggests the mutation arose in a common ancestor who lived centuries ago," Daiger said. "The mutation spread in Europe and North America, and may be common among Acadians in Louisiana. This is called a founder mutation."
UTHealth co-authors include Lori S. Sullivan, Ph.D., Sara J. Bowne, Ph.D., Elizabeth L. Cadena, Cheryl E. Avery and Charles A. Garcia, M.D. Garcia is the Bernice Weingarten Chair in Ophthalmology at UTHealth.

Other co-authors include Daniel C. Koboldt, Robert S. Fulton, George M. Weinstock, Ph.D. and Richard K. Wilson, Ph.D., of the Genome Institute at Washington University in St. Louis; Susan H. Blanton, Ph.D., and Steven Lang of the John P. Hussman Institute for Human Genomics at the University of Miami; Richard A. Lewis, M.D., of Baylor College of Medicine; David G. Birch, Ph.D., Dianna H. Wheaton, Ph.D., and Kaylie Webb-Jones of the Retina Foundation of the Southwest in Dallas; Robert Koenekoop, M.D., Razeck Coussa, Huanan Ren, and Irma Lopez of the McGill University Health Center in Montreal; and Christina Chakarova, Ph.D., of the University College London.

Daiger is also on the faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and the Ruiz Department of Ophthalmology and Visual Science at the UTHealth Medical School.

The report, "A dominant mutation in hexokinase 1 (HK1) causes retinitis pigmentosa," received support from the Hermann Eye Fund, National Institutes of Health (EY007142), National Genome Research Institute and the Foundation Fighting Blindness.

University of Texas Health Science Center at Houston

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to